Carrie House, PhDSan Diego State University Research FoundationSan Diego, CA Role of Macrophages in the Development of Drug-Resistant Ovarian Cancer Stem Cells Following Chemotherapy Ovarian cancer is the deadliest gynecological cancer in the United States and is associated with a high rate of recurrence. Unfortunately, tumors that grow back stop responding to chemotherapy and become […]
Read More
Lori Brotto, PhDThe University of British Columbia2022 Maxine & Julie Eisen Pilot Study Award eSense Cancer: Adapting an online intervention for sexual health concerns to ovarian cancer Sexual health concerns are common after treatment of ovarian cancer, yet effective and accessible treatments to manage those concerns are not available. Dr. Brotto’s team has developed an […]
Read More
Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]
Read More
Hector Franco, PhDUniversity of North Carolina, Chapel Hill2022 Lester and Bernice Smith Pilot Study Award Identifying Drivers of Therapeutic Resistance in Ovarian Cancer at Single-Cell Resolution Ovarian cancer is one of the deadliest cancers among women worldwide. Most women respond well to the standard treatment; however, up to 75% of these patients experience a recurrence […]
Read More
Toni Antalis, PhDUniversity of Maryland, Baltimore2022 Rosser Family Pilot Study Award Emerging roles of MASP activation in ovarian cancer metastasis and acquired chemoresistance While ovarian cancer responds well to initial treatments, it frequently returns due to acquired chemotherapy resistance. Although chemotherapies aim slow or stop tumor growth, cancer cells continue to evolve between chemotherapy cycles. […]
Read More
Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]
Read More
Sarah Gitto, PhDUniversity of Pennsylania2022 Pape Family Scientific Scholar Award Transcriptomic and proteomic analysis of tumor-specific TILs to enhance immunotherapy in ovarian cancer Immunotherapies aim to enhance the immune system’s capability of eliminating disease within the body. Often, immunotherapy for cancer targets a type of immune cell called T cells to activate their ability to […]
Read More